A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD
NCT05081219 HIGHLIGHTS: Agents targeting metabolic or vascular disorders are promising candidates to prevent or treat Alzheimer's disease (AD). Intranasal insulin and empagliflozin were safe alone or in combination for mild cognitive impairment/AD. Insulin improved cognition and markers of inflammation and immune function. Empagliflozin reduced markers of vascular injury and neurodegeneration. A longer, larger trial is needed to validate these results.
Authors
- Christopher T. Whitlow (ORCID: https://orcid.org/0000-0003-2392-8293)
- Sarah A. Gaussoin (ORCID: https://orcid.org/0000-0003-0850-7888)
- Suzanne Craft (ORCID: https://orcid.org/0000-0003-0591-8657)
- Da Ma (ORCID: https://orcid.org/0000-0002-3542-7798)
- Courtney L. Sutphen (ORCID: https://orcid.org/0000-0001-5005-2018)
- Kiran Kumar Solingapuram Sai (ORCID: https://orcid.org/0000-0002-6442-5169)
- Jennifer M. Erichsen (ORCID: https://orcid.org/0000-0002-3807-6903)
- Samuel N. Lockhart (ORCID: https://orcid.org/0000-0002-1161-8346)
- James R. Bateman
- Marc D. Rudolph (ORCID: https://orcid.org/0000-0001-7046-1169)
- Thomas C. Register (ORCID: https://orcid.org/0000-0002-4078-0166)
- Melissa M. Rundle (ORCID: https://orcid.org/0000-0003-4360-216X)
Institutions
- Wake Forest University (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/alz.70704
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88